Antioxidative, Antinitrative, and Vasculoprotective Effects of A Peroxisome Proliferator-Activated Receptor-Gamma Agonist in Hypercholesterolemia

L Tao,HR Liu,E Gao,ZP Teng,BL Lopez,TA Christopher,XL Ma,I Batinic-Haberle,RN Willette,EH Ohlstein,TL Yue
DOI: https://doi.org/10.1161/01.cir.0000097003.49585.5e
IF: 37.8
2003-01-01
Circulation
Abstract:Background—Peroxisome proliferator–activated receptor (PPAR) signaling pathways have been reported to exert anti-inflammatory effects and attenuate atherosclerosis formation. However, the mechanisms responsible for their anti-inflammatory and antiatherosclerotic effects remain largely unknown. The present study tested the hypothesis that a PPAR&ggr; agonist may exert significant endothelial protection by antioxidative and antinitrative effects. Methods and Results—Male New Zealand White rabbits were randomized to receive a normal (control) or a high-cholesterol diet and treated with vehicle or rosiglitazone (a PPAR&ggr; agonist) 3 mg · kg−1 · d−1 for 5 weeks beginning 3 weeks after the high-cholesterol diet. At the end of 8 weeks of a high-cholesterol diet, the rabbits were killed, and the carotid arteries were isolated. Bioactive nitric oxide was determined functionally (endothelium-dependent vasodilatation) and biochemically (the phosphorylation of vasodilator-stimulated phosphoprotein, or P-VASP). Vascular superoxide production, PPAR&ggr;, gp91phox, and inducible nitric oxide synthase (iNOS) expression, and vascular ONOO− formation were determined. Hypercholesterolemia caused severe endothelial dysfunction and reduced P-VASP, despite a marked increase in iNOS expression and total NOx production. Treatment with rosiglitazone enhanced PPAR&ggr; expression, improved endothelium-dependent vasodilatation, preserved P-VASP, suppressed gp91phox and iNOS expression, reduced superoxide and total NOx production, and inhibited nitrotyrosine formation. Conclusions—The PPAR&ggr; agonist rosiglitazone exerted a significant vascular protective effect in hypercholesterolemic rabbits, most likely by attenuation of oxidative and nitrative stresses. The endothelial protective effects of PPAR&ggr; agonists may reduce leukocyte accumulation in vascular walls and contribute to their antiatherosclerotic effect.
What problem does this paper attempt to address?